FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	 -

OMB APPROVAL									
OMB Number: 3235-028									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

					<u> </u>		0 00((11) 01 1110		011110111		iparij 7 tot	0. 20 .								
Name and Address of Reporting Person * Horman Dickard A						2. Issuer Name and Ticker or Trading Symbol Oric Pharmaceuticals, Inc. [ORIC]										5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Heyman Richard A.															2	C Director	or		10% Ov	vner	
(Last) (First) (Middle)							3. Date of Earliest Transaction (Month/Day/Year) 04/28/2020								1	Officer (give title Other (below) below)				specify	
C/O ORIC PHARMACEUTICALS, INC.																					
240 E. GRAND AVE., 2ND FLOOR																					
(Street)					4. 11	4. If Amendment, Date of Original Filed (Month/Day/Year)									Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person					
FRANCISCO CA 94080																Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)																		
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																				
Date					2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr. 5)						es ally Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership					
				С			Code	v	Amount	()	A) or D)	Price	Reported Transact (Instr. 3	ion(s)		ľ	(Instr. 4)				
Common Stock															12	,500		D			
Common Stock					4/28/2020					С		62,500		A	(1)	227	7,500		I	See footnote	
		7	Fable II - E									sed of, onverti				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/Y	d 4 Date, T	I. Transa Code (I	ansaction		5. Number of			rcisa Date	able and	7. Title and A of Securities Underlying Derivative Se (Instr. 3 and 4		Amount ecurity	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	Own S For Oir Or (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exer	e rcisable		xpiration ate	Title	N O	Amount or Jumber of Shares						
Series A Preferred Stock	(1)	04/28/2020			С			62,500		(1)	T	(1)	Comm		52,500	\$ 0.00	0		I	See footnote (2)	

Explanation of Responses:

- 1. The Series A Preferred Stock automatically converted into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock for no additional consideration and has no expiration date.
- 2. The shares are held of record by RAHD Capital, LLC, and the Reporting Person has voting and investment power with respect to such shares.

Remarks:

/s/ Dominic Piscitelli, attorneyin-fact 04/28/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.